Manufacturers come together to identify gaps in vaccine R&D in Europe
In addition, a working group, set up recently, will formulate an agenda for action to pave the way for putting in place a permanent infrastructure securing vaccine R&D

In addition, a working group, set up recently, will formulate an agenda for action to pave the way for putting in place a permanent infrastructure securing vaccine R&D

Cellectis bioresearch Inc, which is located at the Cambridge Innovation Center in Cambridge, Massachusetts, is expected to be responsible for the US-wide promotion of Cellectis bioresearch products and

ImaginAb claimed that its recombinant antibody fragments enable development of tailored, specific imaging agents for drug research. Imanet claimed that its network of Positron Emission Tomography (PET) imaging

NuPathe said that the first trial compared the pharmacokinetics of Zelrix in healthy elderly volunteers to healthy young adult volunteers and the pharmacokinetics of Zelrix applied to the

MorphoSys is expected to provide relevant antigen and antibody molecules, while Proteros is expected to provide advanced x-ray technology and computational chemistry know-how. MorphoSys and Proteros claimed that

AZ-004 is being developed for the treatment of agitation in patients with schizophrenia or bipolar disorder. In the CRL, the FDA has stated that their primary clinical safety

Vickers will be responsible for leading global R&D for Shire HGT and for establishing the strategic direction of the company’s pipeline. Vickers will report to Sylvie Gregoire, president

In the letter, the FDA discussed a number of topics, including the need for additional clinical studies, the appropriate patient population, methods for ensuring safe use, and the

de Garidel started his career in 1983 with the Eli Lilly pharmaceutical Group where he held various roles, mainly finance related, firstly in France, then in the US

As per the terms of the agreement, Lundbeck is expected to pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to